Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · CEO & President | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,278 |
Ending reported balance
After 2026-02-27 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-02-27 · Sale · Disposed 400 · Balance 137,878 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). Row 2 · 2026-02-27 · Sale · Disposed 120 · Balance 137,758 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). Row 3 · 2026-02-27 · Sale · Disposed 240 · Balance 137,518 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). Row 4 · 2026-02-27 · Sale · Disposed 2,510 · Balance 135,008 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). Row 5 · 2026-02-27 · Sale · Disposed 3,278 · Balance 131,730 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). Row 6 · 2026-02-27 · Sale · Disposed 460 · Balance 131,270 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). Row 7 · 2026-02-27 · Sale · Disposed 2,725 · Balance 128,545 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). Row 8 · 2026-02-27 · Sale · Disposed 949 · Balance 127,596 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). Row 9 · 2026-02-27 · Sale · Disposed 2,520 · Balance 125,076 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). Row 10 · 2026-02-27 · Sale · Disposed 3,498 · Balance 121,578 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). Row 11 · 2026-02-27 · Sale · Disposed 15,580 · Balance 105,998 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). Row 12 · 2026-02-27 · Sale · Disposed 5,995 · Balance 100,003 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). Row 13 · 2026-02-27 · Sale · Disposed 1,725 · Balance 98,278 F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.
F2: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).
F4: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).
F5: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).
F6: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).
F7: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).
F8: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).
F9: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).
F10: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).
F11: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).
F12: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).
F13: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).
F14: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).
F15: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ginkgo Bioworks Holdings, Inc.
Report date June 12, 2024 · Filed June 14, 2024
Section 16 reporting ended · disclosed 2024-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 186,002 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 186,002 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,725 | $496.95 | $857,238.75 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 13 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,278 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F15 · price: Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,995 | $496.16 | $2,974,479.20 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 12 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,003 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F14 · price: Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,580 | $495.38 | $7,718,020.40 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 11 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,998 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,498 | $494.33 | $1,729,166.34 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 10 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,578 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,520 | $493.29 | $1,243,090.80 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,076 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 949 | $491.30 | $466,243.70 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,596 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,725 | $490.54 | $1,336,721.50 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,545 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 460 | $489.32 | $225,087.20 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,270 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,278 | $488.27 | $1,600,549.06 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,730 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,510 | $487.13 | $1,222,696.30 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,008 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 240 | $482.84 | $115,881.60 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,518 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $481.50 | $57,780.00 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,758 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:34 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $479.75 | $191,900.00 |
DisclosureSEC source: 0000875320-26-000129 · wk-form4_1772573657.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,878 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,981 | $485.11 | $2,416,332.91 |
DisclosureSEC source: 0000875320-26-000114 · wk-form4_1772147388.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,278 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 6,554 | $483.75 | $3,170,497.50 |
DisclosureSEC source: 0000875320-26-000090 · wk-form4_1771535794.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,259 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 16,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000090 · wk-form4_1771535794.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,813 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 13,041 | $487.76 | $6,360,878.16 |
DisclosureSEC source: 0000875320-26-000070 · wk-form4_1771450516.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,487 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:00 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 8,297 | $468.41 | $3,886,397.77 |
DisclosureSEC source: 0000875320-26-000046 · wk-form4_1770933613.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,528 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 11,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000018 · wk-form4_1769462741.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,825 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 26,972 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000018 · wk-form4_1769462741.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,940 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| August 06, 2025 Filed Aug 7, 2025 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 5,710 | $389.95 | $2,226,614.50 |
DisclosureSEC source: 0000875320-25-000220 · wk-form4_1754598207.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,968 F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. F3 · price: Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53). Read SEC document |
| August 06, 2025 Filed Aug 7, 2025 20:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 4,290 | $389.08 | $1,669,153.20 |
DisclosureSEC source: 0000875320-25-000220 · wk-form4_1754598207.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,258 F1 · price: Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43). F2 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 14,079 | $479.61 | $6,752,429.19 |
DisclosureSEC source: 0000875320-25-000131 · wk-form4_1740779025.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,915 Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,386 | $483.28 | $4,536,066.08 |
DisclosureSEC source: 0000875320-25-000111 · wk-form4_1740604345.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,994 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 6,553 | $463.46 | $3,037,053.38 |
DisclosureSEC source: 0000875320-25-000089 · wk-form4_1740000707.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,380 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 19,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000067 · wk-form4_1739567593.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,933 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 8,300 | $467.98 | $3,884,234.00 |
DisclosureSEC source: 0000875320-25-000044 · wk-form4_1739396757.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,918 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000018 · wk-form4_1738877851.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,218 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:37 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 29,118 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000018 · wk-form4_1738877851.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,890 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,198 | $515.00 | $7,826,970.00 |
DisclosureSEC source: 0000875320-24-000225 · wk-form4_1731445703.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,772 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 20:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,202 | $505.00 | $7,677,010.00 |
DisclosureSEC source: 0000875320-24-000195 · wk-form4_1722543438.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,970 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,202 | $497.00 | $7,555,394.00 |
DisclosureSEC source: 0000875320-24-000187 · wk-form4_1721851538.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,172 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:24 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 105,263 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-24-018713 · form4.xml · derivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 105,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. F2 · derivative.expiration_date: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:24 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 105,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018713 · form4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,565 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0000875320-24-000160 · wk-form4_1717013304.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,565 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,565 | $457.00 | $715,205.00 |
DisclosureSEC source: 0000875320-24-000160 · wk-form4_1717013304.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,374 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,565 | $187.53 | $293,484.45 |
DisclosureSEC source: 0000875320-24-000160 · wk-form4_1717013304.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,202 | $447.00 | $6,795,294.00 |
DisclosureSEC source: 0000875320-24-000156 · wk-form4_1716409296.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,374 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,386 | $431.79 | $4,052,780.94 |
DisclosureSEC source: 0000875320-24-000105 · wk-form4_1709070906.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,507 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 7,019 | $420.58 | $2,952,051.02 |
DisclosureSEC source: 0000875320-24-000074 · wk-form4_1708550975.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,893 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 9,359 | $424.01 | $3,968,309.59 |
DisclosureSEC source: 0000875320-24-000074 · wk-form4_1708550975.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,912 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 8,255 | $422.74 | $3,489,718.70 |
DisclosureSEC source: 0000875320-24-000051 · wk-form4_1707862030.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,271 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,327 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000026 · wk-form4_1707428268.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,526 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 26,972 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000026 · wk-form4_1707428268.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,199 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,516 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000026 · wk-form4_1707428268.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,227 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,077 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · derivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,565 Underlying: Common Stock · 14,077 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,058 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · derivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,058 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,135 | $407.00 | $6,973,945.00 |
DisclosureSEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,711 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 14,077 | $187.53 | $2,639,859.81 |
DisclosureSEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,058 | $155.57 | $475,733.06 |
DisclosureSEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.